Table 2.

Patient characteristics including subpopulations.

	Whole population (n = 440)	Subpopulation with VV-ECMO treatment (n = 67)	Subpopulation without VV-ECMO-treatment (n = 373)	Subpopulation with acute neurological symptoms leading to neuroimaging (n = 64)	Subpopulation with acute PNIF (n = 17)
Age (years mean, SD)	62 ± 15	54 ± 12	64 ± 15	61 ± 14	61 ± 15
% female	23	10	26	14	18
Prior conditions (mean, range)	2 (0–8)	1.5 (0–6)	2 (0–8)	2 (0–8)	2 (0–5)
Prior conditions specified	HTN (46%), CKD (17%), CLD (4%), CHD (9%), CPD (20%), CCD (9%), DM (32%), MAL (8%), OB (26%), DEM (3%), NIC (7%)	HTN (33%), CKD (9%), CLD (5%), CHD (9%), CPD (18%), CCD (2%), DM (21%), MAL (3%), OB (39%), DEM (0%), NIC (16%)	HTN (48%), CKD (18%), CLD (4%), CHD (32%), CPD (21%), CCD (10%), DM (34%), MAL (8%), OB (24%), DEM (3%), NIC (6%)	HTN (36%), CKD (20%), CLD (8%), CHD (30%), CPD (31%), CCD (3%), DM (28%), MAL (11%), OB (38%), DEM (0%), NIC (8%)	HTN (41%), CKD (18%), CLD (6%), CHD (24%), CPD (18%), CCD (6%), DM (18%), MAL (6%), OB (35%), DEM (0%), NIC (6%)
% ECMO; mean duration days, SD	15; 28 ± 22	100; 28 ± 22	0	At the time point of Neuroimaging 38; 13 ± 14	At the time point of Neuroimaging 50; 5 ± 3
% IVM; mean duration days, SD	59; 21 ± 19	100; 36 ± 24	42; 15 ± 12	At the time point of Neuroimaging 88; 16 ± 14	At the time point of Neuroimaging 82; 13 ± 11
%RRT	12	19	10	48	65
Mean length of stay on ICU, SD	15 ± 17	15 ± 17	11 ± 10	Up to the time point of Neuroimaging 13 ± 13	Up to the time point of Neuroimaging 13 ± 11
% Death during hospital stay	38	64	34	53	65

HTN hypertension, CKD chronic kidney disease, CLD chronic liver disease, CHD chronic heart disease, CPD chronic pulmonary disease, CCD chronic cerebro-vascular disease, DM diabetes, MAL malignancy, OB obesity defined by body mass index (BMI; kg/m²) ≥ 30, DEM clinically proven dementia, NIC smoking. Smoking is likely to be underreported.